870987-89-6

Basic information

• Product Name: 1-(4-chloro-1,2,5-thiadiazol-3-yl)-4-methylpiperazine(SALTDATA: HCl)
• Synonyms: 3-chloro-4-(4-methylpiperazin-1-yl)-1,2,5-thiadiazole;1-(4-chloro-1,2,5-thiadiazol-3-yl)-4-methylpiperazine(SALTDATA: HCl)
• CAS NO: 870987-89-6
• Molecular Formula: C₇H₁₁ClN₄S
• Molecular Weight: 218.70704
• Mol File: 870987-89-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-chloro-1,2,5-thiadiazol-3-yl)-4-methylpiperazine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chloro-1,2,5-thiadiazol-3-yl)-4-methylpiperazine(SALTDATA: HCl)(870987-89-6)
• EPA Substance Registry System: 1-(4-chloro-1,2,5-thiadiazol-3-yl)-4-methylpiperazine(SALTDATA: HCl)(870987-89-6)

Safety Data

• Hazardous Substances Data: 870987-89-6(Hazardous Substances Data)

Usage

Chemical structure

Contains a piperazine ring and a chlorothiadiazole group.

Application

Commonly used in pharmaceutical research.

Therapeutic properties

Exhibits potential therapeutic properties.

Biological activity

Presence of the chlorothiadiazole group contributes to its biological activity.

Drug discovery and development

Valuable target for drug discovery and development.

Stability

Hydrochloride salt form enhances stability.

Solubility

Hydrochloride salt form improves solubility.

Pharmaceutical applications

More suitable for use in pharmaceutical applications due to enhanced stability and solubility.

Scientific interest

Garnered interest in the scientific community.

Relevance

Relevant in drug development due to its potential pharmacological properties.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 5728-20-1 3,4-dichloro-1,2,5-thiadiazole 

Relevant articles and documents

Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation

We recently reported the medicinal chemistry reoptimization of a known human tyrosine kinase inhibitor, lapatinib, against a variety of parasites responsible for numerous tropical diseases, including human African trypanosomiasis (Trypanosoma brucei), Chagas disease (T. cruzi), Leishmaniasis (Leishmania spp.), and malaria (Plasmodium falciparum). Herein, we report our continuing efforts to optimize this series against P. falciparum. Through the design of a library of compounds focused on reducing the lipophilicity and molecular weight, followed by an SAR exploration, we have identified NEU-1953 (40). This compound is a potent inhibitor of P. falciparum with an improved ADME profile over the previously reported compound, NEU-961 (3).

Drug Resistance Reversal In Neoplastic Disease

The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.